PRESS RELEASE 2017

• FDA approves Ferring’s CLENPIQ™ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution for colonoscopy prep

The U.S. Food and Drug Administration (FDA) has granted Ferring Pharmaceuticals Inc. approval to market CLENPIQ™ (sodium picosulfate,…

• New Ferring and Aché Laboratórios Farmacêuticos facility opens to optimise drug delivery using nanotechnology

Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos today announced the inauguration of their joint nanotechnology centre in São Paulo…

• Ferring receives Swiss approval for Rekovelle®, the first personalised fertility treatment using an approved dosing algorithm

Ferring Pharmaceuticals announced today that Swissmedic has approved Rekovelle® (follitropin delta) for use in controlled stimulation…

• Ferring strengthens growth hormone franchise Zomacton® through acquisition of ZomaJet™ needle-free injector device

Ferring Pharmaceuticals announced today that it has entered into a definitive agreement with Antares Pharma, Inc…

• Ferring appoints Klaus Dugi as Executive Vice President and Chief Medical Officer

Ferring Pharmaceuticals announced today that Professor Klaus Dugi has been appointed Executive Vice President and Chief Medical Officer…

• Ferring announces new analysis of Rekovelle® data relating to personalised medicine in fertility patients

Ferring Pharmaceuticals announced today a new analysis of Rekovelle® (follitropin delta) data that showed cumulative live birth rates were similar…

• Ferring appoints Lars Peter Brunse to Executive Board

Ferring Pharmaceuticals announced today that Lars Peter Brunse has been appointed Executive Vice President and Chief Production Officer…

• Paul Navarre joins Ferring Pharmaceuticals as Chief Executive Officer of Ferring Holding Inc.

Ferring Pharmaceuticals announced today that Paul Navarre has been appointed Chief Executive Officer of Ferring Holding Inc…

• Ferring appoints Aaron Graff to Executive Board

Ferring Pharmaceuticals announced today that Aaron Graff has been appointed Executive Vice President and Chief Commercial Officer…

• Ferring commits $10 million to March of Dimes to expand research needed to end preterm birth

Ferring Pharmaceuticals and the March of Dimes Foundation announced today that Ferring has committed $10 million to support…